GlassScriptPhysician profile
Kimberly C Stone
NPI 1093819369
$4,391.35
in general payments reported to CMS, 2019-2025
29 companies · $762 in 2025
The $762 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $331 · 2021: $563 · 2022: $674 · 2023: $755 · 2024: $737 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.19 |
| Education | $227.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.19 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Janssen Biotech, INC. | $515.34 | 2019-2024 | Tremfya |
| Genzyme Corporation | $465.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.74 | 2020-2025 | Dupixent, Libtayo |
| Incyte Corporation | $264.17 | 2021-2024 | Opzelura |
| Allergan, INC. | $253.31 | 2019-2022 | |
| Pfizer INC. | $251.77 | 2019-2025 | |
| Merz North America, INC. | $222.14 | 2019-2025 | Xeomin |
| Sun Pharmaceutical Industries INC. | $218.84 | 2020-2025 | Odomzo, Blu-U, Winlevi |
| Galderma Laboratories, L.P. | $151.86 | 2019-2025 | Dysport |
| Lilly USA, LLC | $138.75 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.25 | 2019-2025 | Jublia, Cabtreo |
| Leo Pharma INC. | $107.56 | 2021-2025 | Adbry |
| Ucb, INC. | $104.96 | 2020-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $94.58 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.09 | 2022-2023 | Sotyktu |
| Almirall LLC | $52.17 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $45.34 | 2020-2021 | |
| Dermira, INC. | $42.44 | 2019-2020 | |
| Celgene Corporation | $37.78 | 2019 | |
| Mayne Pharma Commercial LLC | $36.06 | 2019 | |
| Biofrontera INC. | $34.40 | 2019-2025 | Bf-Rhodoled |
| Journey Medical Corporation | $29.63 | 2022 | |
| Amgen INC. | $22.44 | 2022 | |
| Merck Sharp & Dohme LLC | $18.68 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.32 | 2025 | Zoryve |
| Epi Health, LLC | $13.69 | 2021 | |
| Sientra, INC. | $12.37 | 2019 | |
| Organon LLC | $8.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.